Navigation Links
Hard to Treat Diseases (HTDS) Awarded Two Antibiotics Certificates For Chile
Date:3/15/2010

SHENZHEN, CHINA, March 15 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS; http://www.htdsmedical.com/) is pleased to announce that the Chilean government approved two of the company's penem injectables.

Following 18 months of testing and negotiations, Chilean ISP (Ministry of Health) approved two of HTDS' penem injectables, Meropenem for Injection (MEINEN) and Imipenem for Injection (IMINEN). HTDS received the registration certificate for these two medications from the Chilean ISP and the company prepares to ship its products to this emerging South American market. Meropenem and Imipenem See link http://www.cdc.gov/ncidod/dhqp/ar_lab_imipenem.html are antibiotics with wide range of efficiency, treating infections in lungs, heart, blood, bone, stomach, etc., and offer great market value for the producers and distributors.

HTDS' CEO Terry Yuan said, "We are happy that we finalized the test stage for these two products and received the ISP's certificate. The certificate will strengthen our supply capacity for the market. HTDS - Mellow Hope through our Chilean agent holds a powerful position on the local injectables market. Aligning these two facts, we believe that these two antibiotics will succeed in Chile and bring solid sales numbers to HTDS. Overall, penem injectables have great market potential globally, and we continue to seek new market and distribution opportunities around the world." More on penem injectables can be found by visiting www.oxfordjournals.org

The company reminds our shareholders and followers that the company does not subscribe to the PinkSheets.com Filing Service. Its IR company web site section "CLIENT SUPPORT" TAB www.minamargroup.net or this direct link http://minamarmarketinggroup.helpserve.com/should be reviewed by its followers for further updates on this and other business matters. Non-newsworthy events are not press released however posted on this separate support sites to keep our followers advised of day-to-day events, and the company corporate web site. For any matters relating to retail investor queries or to send us the company directly a message please click on the "INVESTOR SUPPORT" TAB or this direct link www.minamargroup.net/helpdesk.

To be included in company's email database for press releases, industry updates, and non-weekly activity at the company that may or may not be news released, please subscribe or opt in mailer at www.minamargroup.com/updates.

Safe Harbor Statement

Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For medical and scientific dialogue inquiry only, please contact medicalinfo@htdsmedical.com; For any corporate matters, please contact www.minamargroup.com/helpdesk

SOURCE Hard to Treat Diseases

Back to top
'/>"/>
SOURCE Hard to Treat Diseases
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Vertebroplasty: Integral to treating back pain in blood marrow cancer patients
2. Combination Treatment May Help Depressed Alcoholics
3. New study identifies best treatment for childhood epilepsy
4. Brain Science Institute announces license agreement to develop treatments for neurological disease
5. Haven Behavioral War Heroes Hospital to Offer Comprehensive Psychiatric Treatment for Military Service Members
6. The Elizabeth Birt Center for Autism Law and Advocacy (EBCALA) Objects to Media Reports Tainting Autism Doctors and Misrepresenting Autism Treatments
7. Florida Surgeon Demonstrates Kidney Sparing Cancer Treatment in Live Surgical Webcast
8. Heat Therapy Helps Treat U.S. Soldiers Infections
9. Discovery of cellular switch may provide new means of triggering cell death, treating disease
10. Hard to Treat Diseases (HTDS) Acquired Varicella Approval in Guatemala
11. Whistleblower Alerts Americans to Dangers of Risky Unapproved Treatment for Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... , ... December 03, 2016 , ... While James Earl ... serving as host for in a show called "Front Page". One of the forthcoming ... years, breast cancer rates have plummeted in large part due to early detection. Like ...
(Date:12/4/2016)... Washington DC (PRWEB) , ... December 04, 2016 , ... ... Environmental, one of the most certified and experienced Indoor Air Quality Companies in VA, ... Assessment and Remediation Regulations. , The new mold law in the district ...
(Date:12/2/2016)... ... December 02, 2016 , ... On Dec. 2, 2016, CURE® magazine ... San Diego honoring the 2016 MPN Heroes—eight individuals who have made a difference in ... and beyond the standard of care, demonstrating leadership within the MPN community and/or a ...
(Date:12/2/2016)... ... 2016 , ... Center for Autism and Related Disorders (CARD) Portland today announced ... disorder (ASD) and other developmental disabilities. The group, which is being launched with the ... the opportunity to share stories and advice, seek help, and continue their education on ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... California, will be included in the 2016 “Guide to America’s Top Plastic Surgeons” ... on the amalgamation of their education, experience, and professional associations. , One ...
Breaking Medicine News(10 mins):
(Date:12/4/2016)... 3, 2016 Johnson & Weaver, LLP announces that ... of Zimmer Biomet Holdings, Inc. (NYSE: ZBH ) ... 31, 2016 (the "Class Period"). Zimmer Biomet provides ... orthopaedic reconstructive products, such as knee and hip reconstructive products. ... , , ...
(Date:12/4/2016)...   Pairnomix, LLC, a genetic research company and ... the White House, today announced that findings from its first ... candidate therapies for a patient with epileptic encephalopathy caused by ... at the 70 th Annual Meeting of the ... , December 2-6, 2016.  Pairnomix, unique process involves ...
(Date:12/4/2016)...  Results from the Phase II SUSTAIN study show ... the median annual rate of sickle cell-related pain crises ... p=0.010) in patients with or without hydroxyurea therapy 1 ... featured in the official press briefing at the 58 ... and presented during the Plenary Scientific Session tomorrow (Abstract ...
Breaking Medicine Technology: